Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA7 | P43166 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11576641 | 0.83 | PDK2 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24941116 | 0.82 | PDK2 (0.45) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL12261016 | 0.82 | CSNK2A1 (0.62) | L3MBTL1HSP90AA1ALDH1A1MEN1MAPT | |
| SCHEMBL17774838 | 0.80 | KDM4E (0.60) | L3MBTL1CA1CA2ALOX5PTGS2 | |
| SCHEMBL3814807 | 0.80 | L3MBTL1 (0.56) | L3MBTL1CA1CA2PDK2HSP90AA1 | |
| SCHEMBL5065113 | 0.80 | PDK2 (0.47) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL3216800 | 0.80 | CA1 (0.60) | L3MBTL1CA1CA2ALDH1A1MEN1 | |
| SCHEMBL12261048 | 0.80 | CES2 (0.68) | L3MBTL1ALDH1A1CYP2C9MEN1MAPT | |
| SCHEMBL5065100 | 0.79 | PDK2 (0.46) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL6880901 | 0.78 | PDK2 (0.53) | L3MBTL1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312349-A1 | METHOD OF MAKING AND USING MEMBRANE | GENERAL ELECTRIC COMPANY (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080207822-A1 | COMPOSITION AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008103599-A2 | COMPOSITION, ITS USE IN THE PREPARATION OF MEMBRANES, AND SYSTEMS COMPRISING THE MEMBRANES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-08-28 | — | — | WO | disclosed |
| US-20080203012-A1 | MEMBRANE, APPARATUS, AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-6933403-B2 | Mono carbonylation of benzene diols | BIOLAND CO., LTD. (KR) | 2005-08-23 | — | — | US | disclosed |
| US-20040260114-A1 | Mono carbonylation of benzene diols | HYUNDAI BIOLAND CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
| WO-2003033449-A1 | MONO CARBONYLATION OF BENZENE DIOLS | BIOLAND CO., LTD (KR) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260114-A1 | Mono carbonylation of benzene diols | CBR1, CBR3, CYP1A1 | L3MBTL1 3938/4885CA12 60/4885CA1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.